Phase II single-arm, single-institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC)

被引：0
|
作者：
O'Reilly, E. M.
Jarnagin, W. R.
Brennan, M. F.
Winston, C.
Tang, L. H.
Capanu, M.
Schattner, M.
Chen, L. Y.
DeMatteo, R. P.
DiMaio, C. J.
D'Angelica, M. I.
Kurtz, R. C.
Klimstra, D. S.
Lowery, M. A.
Coit, D. G.
Reidy, D. L.
Allen, P. J.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4065
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
    Zhaoqing Tang
    Yan Wang
    Yiyi Yu
    Yuehong Cui
    Liang Liang
    Chen Xu
    Zhenbin Shen
    Kuntang Shen
    Xuefei Wang
    Tianshu Liu
    Yihong Sun
    BMC Medicine, 20
  • [32] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Jamie E. Chaft
    Filiz Oezkan
    Mark G. Kris
    Paul A. Bunn
    Ignacio I. Wistuba
    David J. Kwiatkowski
    Dwight H. Owen
    Yan Tang
    Bruce E. Johnson
    Jay M. Lee
    Gerard Lozanski
    Maciej Pietrzak
    Michal Seweryn
    Woo Yul Byun
    Katja Schulze
    Alan Nicholas
    Ann Johnson
    Jessica Grindheim
    Stephanie Hilz
    David S. Shames
    Chris Rivard
    Eric Toloza
    Eric B. Haura
    Ciaran J. McNamee
    G. Alexander Patterson
    Saiama N. Waqar
    Valerie W. Rusch
    David P. Carbone
    Nature Medicine, 2022, 28 : 2155 - 2161
  • [33] Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
    Chaft, Jamie E.
    Oezkan, Filiz
    Kris, Mark G.
    Bunn, Paul A.
    Wistuba, Ignacio I.
    Kwiatkowski, David J.
    Owen, Dwight H.
    Tang, Yan
    Johnson, Bruce E.
    Lee, Jay M.
    Lozanski, Gerard
    Pietrzak, Maciej
    Seweryn, Michal
    Byun, Woo Yul
    Schulze, Katja
    Nicholas, Alan
    Johnson, Ann
    Grindheim, Jessica
    Hilz, Stephanie
    Shames, David S.
    Rivard, Chris
    Toloza, Eric
    Haura, Eric B.
    McNamee, Ciaran J.
    Patterson, G. Alexander
    Waqar, Saiama N.
    Rusch, Valerie W.
    Carbone, David P.
    NATURE MEDICINE, 2022, 28 (10) : 2155 - +
  • [34] Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial)
    Okada, Ken-ichi
    Kimura, Kenjiro
    Yamashita, Yo-Ichi
    Shibuya, Kazuto
    Matsumoto, Ippei
    Satoi, Sohei
    Yoshida, Kazuhiro
    Kodera, Yasuhiro
    Akahori, Takahiro
    Hirono, Seiko
    Eguchi, Hidetoshi
    Asakuma, Mitsuhiro
    Tani, Masaji
    Hatano, Etsuro
    Ikoma, Hisashi
    Ohira, Go
    Hayashi, Hiromitsu
    Wan, Ke
    Shimokawa, Toshio
    Kawai, Manabu
    Yamaue, Hiroki
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (06): : 997 - 1008
  • [35] Neoadjuvant pamiparib in patients with newly diagnosed advanced ovarian cancer: A single-arm, prospective phase II trial
    Liu, Jing
    Hu, Dan
    Li, Li
    Zang, Lele
    Zhu, Fei
    Zhu, Mingxuan
    Zhang, Huiqi
    Chang, Lele
    Xu, Qin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial
    Li, Kaiwen
    Zhong, Wenlong
    Fan, Jinhai
    Wang, Shaogang
    Yu, Dexin
    Xu, Tao
    Lyu, Jiaju
    Wu, Shaoxu
    Qin, Tao
    Wu, Zhuo
    Xu, Longhao
    Wu, Kaijie
    Liu, Zheng
    Hu, Zhiquan
    Li, Fan
    Wang, Jinyou
    Wang, Qi
    Min, Jie
    Zhang, Zhiqiang
    Yu, Luping
    Ding, Sentai
    Huang, Longfei
    Zhao, Tingting
    Huang, Jian
    Lin, Tianxin
    NATURE CANCER, 2024, 5 (10) : 1465 - 1478
  • [37] Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study
    Bahce, Idris
    Dickhoff, Chris
    Schneiders, Famke L.
    Veltman, Joris
    Heineman, David J.
    Hashemi, Sayed M. S.
    Vrijmoet, Anne
    Houda, Ilias
    Ulas, Ezgi B.
    Bakker, Joyce
    van de Ven, Peter
    Bouwhuis, Natalja
    Meijboom, Lilian J.
    Oprea-Lager, Daniela E.
    van Maldegem, Febe
    Fransen, Marieke F.
    de Gruijl, Tanja D.
    Radonic, Teodora
    Senan, Suresh
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)
  • [38] Neoadjuvant camrelizumab plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial
    Gao, Jin
    Qian, Liting
    Zhou, Lingran
    Sun, Bin
    He, Jian
    Wang, Ru
    Zhang, Yangyang
    Yang, Liping
    Zhou, Yan
    Yang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trial
    Zhu, X.
    Sun, L.
    Song, N.
    Sun, F.
    Yang, J.
    Duan, L.
    Zhao, D.
    He, W.
    Luo, J.
    Zhang, H.
    Wu, C.
    Zhu, Y.
    Zhang, P.
    Jiang, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S942 - S942
  • [40] The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
    Huang, Nai-si
    Wei, Wen-jun
    Xiang, Jun
    Chen, Jia-ying
    Guan, Qing
    Lu, Zhong-wu
    Ma, Ben
    Sun, Guo-hua
    Wang, Yu-long
    Ji, Qing-hai
    Wang, Yu
    THYROID, 2021, 31 (12) : 1808 - 1813
12345